Could a lower drug dose make stem cell transplants safer for blood cancer patients?
NCT ID NCT03983850
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study looks at whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent complications like graft-versus-host disease (GVHD) while still controlling blood cancers. About 105 people aged 15-65 with leukemia, lymphoma, or multiple myeloma will take part. The goal is to make transplants safer and reduce side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.